

**GRANGEX AB PEA confirms robust economics for Sydvaranger – mapping the road to financial close in H2'25** Johan Widmark | 2025-01-24 11:00

With the release of a Preliminary Economic Assessment (PEA) for the restart of the Sydvaranger mine, GRANGEX now has more clarity on the path ahead. Based on a price forecast of USD 106-145 per ton for 2027-2045, total production of 54 million tonnes of 70% ultra-high-grade iron ore concentrate, and all permits in place, the PEA supports a healthy IRR of 47% and a post-tax NPV(8) of USD 925 million. GRANGEX now targets completing a DFS for Sydvaranger by July 2025, achieving financial close in 2025, and commencing first production in early 2027. All in all, we now estimate an rNPV-based fair value for the GRANGEX share at SEK 82 per share, contingent on resolving the obstacles related to power supply at Dannemora and the management successfully raising the funding needed to develop the assets.

### **Option B: B for Base Case**

The PEA outlines two options. The fast-track, low-CAPEX option, A, utilises the existing infrastructure with minor upgrades to enhance mill throughput. Processes will be upgraded to produce DR-grade pellet feed. Option B, which is the base case, assumes the first three years will follow Option A. Thereafter, the Bjørnevatn pit ore will be accessed at the earliest scheduled opportunity, and the crusher will be relocated to facilitate this option. This approach involves starting slower, with gradual investments, to increase capacity and access an additional 35 Mt of iron ore. The PEA presents a lower initial CAPEX than our previous estimate (USD 348m vs USD 515m) but higher total maintenance CAPEX (USD 139m vs USD 66m). OPEX, however, aligns with expectations (USD 62/ton vs USD 61/ton) and reflects a steady-state OPEX (over 15 years) of USD 54/ton. Notably, the earlier model assumed a 68% concentrate grade, while GRANGEX now targets a concentrate product with a FeMag grade above 70%.

Regarding the timeline, Option B includes a four-year construction period (incorporating Option A). Production will begin during the development phase, yielding a total 8.4 Mt of DR-grade concentrate. Steady-state production will commence in Year 5, delivering 3.0 Mtpa of DR-grade concentrate. All in all, the PEA shows a post-tax NPV(8) of USD 9 25m, slightly lower than the previous estimate of USD 1,108m.

### Solid fair value support but financing remains an issue

Combined with our post-tax NPV calculation for Dannemora, we now find support for a total NPV attributable to existing shareholders, net of existing Net IB Debt of SEK 322m at the end of Q3, amounting to SEK 1,150m or SEK 82 per share. This value, however, is contingent on management successfully raising the capital needed to advance the projects. While we estimate the full financing requirement to reach USD 665m through a combination of equity and debt, Option B allows GRANGEX to start small, requiring only USD 99m in capital during Year 1. Additionally, our model shows cash flows (excluding CAPEX and financial expenses) of USD 55m in the first three years of operation, which helps ease the pressure on external financing.

Furthermore, we see a fair chance that both Anglo American (which has already committed to supporting the Sydvaranger financing package with USD 50m and could likely contribute more) and the Norwegian government, along with other public agencies, will step up to provide various forms of financial support, along with other conventional and unconventional financing institutions. Such contributions could quickly change the outlook and make the financing target appear less daunting.

# **GRANGEX AB**

	_
Current Price, SEK	9.7
Market Capitalisation (MSEK)	136.0
Number of Shares (Millions)	14.016
Cash (MSEK)	146.5
Net IB Debt (MSEK)	322.4
Enterprise Value (MSEK)	458.3
Market	Nordic SME
hay have have have a second se	18 16 14 12 55 8
mar 24 maj 24 jul 24 sep 24	nov 24 jan 25

## Timeline & Value attributable to current sharehoders

	2024		2025		202	6	2027	
	H1	H2	H1	H2	H1	H2	H1	H2
Dannemora			Final Empty Initiate Investment water construc. Decision		Production start			
Sydvaranger	First Installment of USD 20m		Deferred Updated PEA Feasibility Study Deferred USD 13m and Final Investment Decision		Production start			
	USDM	SEKM					USDM	SEKM
(A) NPV Dannemora Unlevered (8%)	247	2,598	(F) NPV Syndvaranger Unlevered (8%)		985	10,340		
(B) New Equity	55	578	(G) Anglo Financing		50	525		
(C) New Debt Dannemora 160 1,680 (H) Ne		(H) New Equity Sydvaranger		200	2,100			
				(I) New Debt	t Sydvaranger		250	2,625
(D) NPV attributable to GRANGEX (Unl	32	341	(J) NPV attributable to GRANGEX (Unl		785	5,090		
Risk adjustment		90%	Risk adjustment			20%		
(E) rNPV Dannemora	29	307	-	(K) rNPV Sy	dvaranger		97	1,018
(L) Apaptite project							9	99
(M) Sala Bly							5	50
(N) Total Equity NPV	(6	E+K+L+M)			140	1,474		
Existing Debt							31	322
Implied Equity Value Existing Sharehol	ders GRANGE	X, MSEK						1,150
Implied value, per share, SEK								82

Source: Emergers

### Power issue at Dannemora

As for Dannemora, GRANGEX has faced challenges regarding power supply, as Vattenfall and Svenska Kraftnät, despite "intensive efforts" from GRANGEX, have not yet confirmed their ability to deliver the necessary power to the mine. This remains a significant concern. Without clarity on this issue, GRANGEX cannot proceed with project financing, which has delayed the procurement process for Dannemora. Considering that public institutions in Sweden are not known for moving quickly—except when imposing regulatory restrictions there is a risk that this process may be prolonged. As a result, Sydvaranger is now expected to become GRANGEX's first producing mine. For now, we have chosen to delay the timetable for Dannemora by six months in our model.

### Financing: A Key Issue to Resolve in H2 2025

The GRANGEX share has struggled to move closer to its fair value, largely due to uncertainties surrounding the company's future financing needs and the scale of those requirements. While uncertainty around the power supply for Dannemora persists, the PEA for Sydvaranger should provide some basis of confidence for shareholders ahead of the DFS and major financing activities scheduled for late 2025.

### Key milestones for investors

We now look forward to:

- Resolution of the power issue at Dannemora
- Final investment decision and commencement of drainage of Dannemora
- Updated DFS for Sydvaranger by mid 2025
- The major capital raise in 2025
- Final Investment Decision for Sydvaranger
- Production start in Dannemora now in 2027

### Clearer picture of the balance sheet impact of Sydvaranger

With Sydvaranger now in the books for the first time, Q2 was the first report to shed some interesting light on the details of the deal, and the impact on the

balance sheet. The royalty agreements with Anglo American are reported as a financial liability at amortized cost. Royalty payments will be made in line with the delivery and sale of iron ore during the planned production (11 years for Dannemora and 19 years for Sydvaranger), with amortization calculated per ton of ore. An accounting interest is added to the liability, with the interest continuously reported in the income statement. However, no cash flow-impacting interest payment will be made. The same applies to the deferred payment and the loan to Orion, as well as the loan to DNB, where the interest is added to the liability, allowing the company's entire cash position, at SEK 110m at the end of Q3'24, to be used for project development.

### Overview of Long-term Debt

SEKm	Q2'24	Q3'24
Royalty Agreement Anglo American	309.6	309.6
Deferred consideration Orion	137.9	137.9
Assumed loan Orion (20% acc. intr.)	246.0	246.0
Assumed loan DNB	48.9	48.9
Other	0.1	0.1
Total	742.6	742.6
Interest Bearing for NIBD	432.9	432.9
Cash	146.53	110.52
Net IB Debt	286.4	322.4

Source: GRANGEX, Emergers

#### Disclaimer

#### General disclaimer and copyright

This material is not intended to be financial advice. This material has been commissioned by the Company in question and prepared and issued by Emergers, in consideration of a fee payable by the Company. Emergers charges a standard fee for the production and broad dissemination of a detailed note following by regular update notes. Fees are paid upfront in cash without recourse. Emergers may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained herein represent those of the research analyst at Emergers at the time of publication. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers' own. Forward-looking information or statements contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Emergers shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this material.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Emergers's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in this material may not be eligible for sale in all jurisdictions or to certain categories of investors. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.

Investment in securities mentioned: Emergers has a restrictive policy relating to personal dealing and conflicts of interest. Emergers does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Emergers may have a position in any or related securities mentioned in this report, subject to Emergers' policies on personal dealing and conflicts of interest.

Copyright: Copyright 2023 Incirrata AB (Emergers)

#### **United Kingdom**

This document is prepared and provided by Emergers for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

#### **United States**

Emergers relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Emergers does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Johan Widmark | Tel: 0739196641 | Mail: johan@emergers.se

Emergers Incirrata AB Enbacken 16 187 44 Täby Sweden Phone: 0739 – 19 66 41 Email: johan@emergers.se Corp reg no: 556815-7837